{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:56Z","timestamp":1784700416123,"version":"3.55.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite deployment of vector control and prevention strategies, dengue remains a substantial threat to public health. Development of an effective vaccine against dengue has been challenging due to the need for simultaneous immunity against all four dengue virus serotypes, durable protection regardless of prior dengue exposure, and the complex epidemiological patterns of serotype co-circulation. As part of the clinical development of TAK-003, a live attenuated tetravalent dengue vaccine based on a DENV-2 backbone, extensive profiling of post-vaccination immune responses has been performed in participants who were dengue-naive or previously-exposed at baseline across dengue-endemic and non-endemic regions. In this review, we summarise the magnitude, quality, and functionality of humoral and cellular immune responses following the first and second doses of TAK-003 across age, region, and DENV serotype. We also outline long-term persistence and durability, ongoing investigations into correlates of protection, age-stratified responses, and evidence on co-administration with other vaccines.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1851238","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:25Z","timestamp":1784699665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program"],"prefix":"10.3389","volume":"17","author":[{"given":"Sanja","family":"Mandaric","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"El Hindi","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo J. M.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases, Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel, Sistema Nacional de Investigaci\u00f3n at SENACYT, Centro de Vacunaci\u00f3n Internacional (Cevaxin)","place":["Panama City, Panama"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Borja-Tabora","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Research Institute for Tropical Medicine","place":["Muntinlupa, Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Friberg","sequence":"additional","affiliation":[{"name":"Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roubinis","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Lausanne University Hospital and University of Lausanne","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Currier","sequence":"additional","affiliation":[{"name":"Viral Diseases Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Sharma","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","unstructured":"Dengue and severe dengue\n          \n          2024"},{"key":"B2","unstructured":"Global strategy for dengue prevention and control 2012-2020\n          \n          2012"},{"key":"B3","unstructured":"Global strategic preparedness, readiness and response plan for dengue and other aedes-borne arboviruses\n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2542-5196(21)00132-7","article-title":"Projecting the risk of mosquito-borne diseases in a warmer and more populated world: A multi-model, multi-scenario intercomparison modelling study","volume":"5","author":"Col\u00f3n-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Planet Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B6","unstructured":"Schaefer\n              TJ\n            \n            \n              Panda\n              PK\n            \n            \n              Wolford\n              RW\n            \n          \n          Dengue fever\n          \n          2024"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.045","article-title":"Immune correlates of protection for dengue: State of the art and research agenda","volume":"35","author":"Katzelnick","year":"2017","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/s1473-3099(16)30473-x","article-title":"Dengue: Knowledge gaps, unmet needs, and research priorities","volume":"17","author":"Katzelnick","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001831","article-title":"Challenges on the development of a dengue vaccine: A comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023","journal-title":"J Gen Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/srep22303","article-title":"Antibody-dependent enhancement of dengue virus infection inhibits Rlr-mediated type-I Ifn-independent signalling through upregulation of cellular autophagy","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02798-x","article-title":"Severe disease during both primary and secondary dengue virus infections in pediatric populations","volume":"30","author":"Aggarwal","year":"2024","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s40249-021-00908-2","article-title":"Clinical predictors of severe dengue: A systematic review and meta-analysis","volume":"10","author":"Tsheten","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267186","article-title":"Risk and predictive factors for severe dengue infection: A systematic review and meta-analysis","volume":"17","author":"Yuan","year":"2022","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004398","article-title":"Incomplete protection against dengue virus type 2 re-infection in Peru","volume":"10","author":"Forshey","year":"2016","journal-title":"PloS NeglTrop Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw099","article-title":"Homotypic dengue virus reinfections in Nicaraguan children","volume":"214","author":"Waggoner","year":"2016","journal-title":"J Infect Dis"},{"key":"B19","volume-title":"Guidelines for the clinical evaluation of dengue vaccines in endemic areas","year":"2008"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2490295","article-title":"Tak-003: Development of a tetravalent dengue vaccine","volume":"24","author":"S\u00e1ez-Llorens","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: A randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (Tak-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (Tak-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (Tak-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(25)00382-2","article-title":"Effectiveness of the Tak-003 dengue vaccine in adolescents during the 2024 outbreak in S\u00e3o Paulo, Brazil: A test-negative, case-control study","volume":"26","author":"Ranzani","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B27","unstructured":"Vaccines and immunization: Dengue\n          \n          2025"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: A new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1004608","article-title":"Innate and adaptive immune evasion by dengue virus","volume":"12","author":"Lee","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1017\/s1462399408000665","article-title":"Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection","volume":"10","author":"Pierson","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.022","article-title":"Complement and humoral immunity","author":"Carroll","year":"2008","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.09.015","article-title":"Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an Igg subclass-specific manner","volume":"2","author":"Mehlhop","year":"2007","journal-title":"Cell Host Microbe"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.12.7466-7477.2005","article-title":"Complement activation is required for induction of a protective antibody response against West Nile virus infection","volume":"79","author":"Mehlhop","year":"2005","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.08.019","article-title":"Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism","volume":"393","author":"Mehlhop","year":"2009","journal-title":"Virology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.09.003","article-title":"Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus","volume":"6","author":"Mehlhop","year":"2009","journal-title":"Cell Host Microbe"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00400-21","article-title":"The specificity of the persistent Igm neutralizing antibody response in Zika virus infections among individuals with prior dengue virus exposure","volume":"59","author":"Calvert","year":"2021","journal-title":"J Clin Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1016\/j.cell.2022.10.023","article-title":"A Zika virus-specific Igm elicited in pregnancy exhibits ultrapotent neutralization","volume":"185","author":"Singh","year":"2022","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102733","DOI":"10.1016\/j.ebiom.2020.102733","article-title":"Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural Denv infection","volume":"54","author":"Waickman","year":"2020","journal-title":"eBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad122","article-title":"Soluble Ns1 antagonizes Igg- and Iga- mediated monocytic phagocytosis of Denv infected cells","volume":"228","author":"Waldran","year":"2023","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41467-023-44330-8","article-title":"Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype","volume":"15","author":"Bos","year":"2024","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00244-24","article-title":"Dengue and severe dengue","volume":"38","author":"Kalimuddin","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir012","article-title":"Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection","volume":"203","author":"Hatch","year":"2011","journal-title":"J Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized Cx3cr1+ cytotoxic Cd4+ T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/vaccines13111103","article-title":"Cd4(+) T cells are key to shaping a protective humoral immunity in primary dengue 2 virus infection: Implications for rational vaccine design","volume":"13","author":"Miranda-Santiago","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00531","article-title":"Cytotoxic Cd4 T cells: Differentiation, function, and application to dengue virus infection","volume":"7","author":"Tian","year":"2016","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4614-6217-0_9","article-title":"Memory Cd8+ T cell protection","volume":"785","author":"Remakus","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B47","first-page":"2026.01.30.702935","article-title":"Dengue virus-specific memory B cell subsets differ as a function of infection history","volume-title":"bioRxiv","author":"Singh","year":"2026"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/infdis\/jiaa120","article-title":"Primary and secondary dengue virus infections elicit similar memory B-cell responses, but breadth to other serotypes and cross-reactivity to Zika virus is higher in secondary dengue","volume":"222","author":"Andrade","year":"2020","journal-title":"J Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","volume":"27","author":"D\u00f6rner","year":"2007","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179771","article-title":"Frequency of dengue virus\u2013specific T cells is related to infection outcome in endemic settings","volume":"10","author":"G\u00e1lvez","year":"2025","journal-title":"JCI Insight"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir607","article-title":"B-cell responses during primary and secondary dengue virus infections in humans","volume":"204","author":"Mathew","year":"2011","journal-title":"J Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01359","article-title":"Longitudinal analysis of memory B and T cell responses to dengue virus in a 5-year prospective cohort study in Thailand","volume":"10","author":"S\u00e1nchez-Vargas","year":"2019","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.antiviral.2013.03.008","article-title":"The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker","volume":"98","author":"Muller","year":"2013","journal-title":"Antiviral Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1038\/s41598-017-07308-3","article-title":"Antibodies against modified NS1 wing domain peptide protect against dengue virus infection","volume":"7","author":"Lai","year":"2017","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2121","article-title":"The association between dengue viremia kinetics and dengue severity: a systemic review and meta-analysis","volume":"30","author":"Morsy","year":"2020","journal-title":"Rev Med Virol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nate Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715136","article-title":"Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines","volume":"12","author":"Pinheiro","year":"2021","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01778","article-title":"Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003","volume":"10","author":"Waickman","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PloS NeglTrop Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac272","article-title":"Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine","volume":"226","author":"DeMaso","year":"2022","journal-title":"J Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the type-specific and cross-reactive B-cell responses elicited by a live-attenuated tetravalent dengue vaccine","volume":"223","author":"Michlmayr","year":"2021","journal-title":"J Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz081","article-title":"Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate","volume":"221","author":"Sharma","year":"2020","journal-title":"J Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac476","article-title":"Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system","volume":"227","author":"Nascimento","year":"2023","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa406","article-title":"Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study","volume":"225","author":"Sirivichayakul","year":"2022","journal-title":"J Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab064","article-title":"Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine","volume":"225","author":"Tsuji","year":"2022","journal-title":"J Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.01.016","article-title":"Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting","volume":"40","author":"Tricou","year":"2022","journal-title":"Vaccine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"key":"B77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/cid\/ciae369","article-title":"Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group","volume":"80","author":"Borja-Tabora","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.22-0673","article-title":"Effect of the tetravalent dengue vaccine TAK-003 on sequential episodes of symptomatic dengue","volume":"108","author":"S\u00e1ez-Llorens","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae222","article-title":"Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or yellow fever vaccination","volume":"230","author":"Sirivichayakul","year":"2024","journal-title":"J Infect Dis"},{"key":"B80","article-title":"Diversity, quality, magnitude and functionality of the humoral response to a live-attenuated tetravalent dengue vaccine in pediatric participants from a phase 3 efficacy trial","volume-title":"41st Annual Meeting of the European Society for Paediatric Infectious Diseases. Lisbon, Portugal, 2023","author":"Sharma","year":"2023"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127558","article-title":"Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine","volume":"62","author":"El Hindi","year":"2025","journal-title":"Vaccine"},{"key":"B82","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41541-024-00967-0","article-title":"Long term T cell response and safety of a tetravalent dengue vaccine in healthy children","volume":"9","author":"Mandaric","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv258","article-title":"CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate","volume":"212","author":"Chu","year":"2015","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110341","article-title":"Transcriptome-wide changes in gene expression, splicing, and lncRNAs in response to a live attenuated dengue virus vaccine","volume":"38","author":"Kim","year":"2022","journal-title":"Cell Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy063","article-title":"Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate","volume":"217","author":"Swanstrom","year":"2018","journal-title":"J Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1038\/s41467-019-11634-7","article-title":"Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling","volume":"10","author":"Waickman","year":"2019","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128373","article-title":"Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: an open-label phase 2 trial","volume":"77","author":"Mandaric","year":"2026","journal-title":"Vaccine"},{"key":"B93","article-title":"Long-term safety and cell-mediated immunity before and after booster of tetravalent dengue vaccine TAK-003 in healthy adults in dengue nonendemic United States","volume-title":"Presented at the Northern European Conference on Travel Medicine (NECTM10), 3-5 June 2026, Belfast, UK","author":"Escudero","year":"2026"},{"key":"B94","unstructured":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose\n          \n          ClinicalTrials.gov"},{"key":"B95","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1016\/j.vaccine.2023.09.049","article-title":"Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): a randomized placebo-controlled trial in US adults","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011124","article-title":"Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: a phase 3 randomized, controlled study","volume":"17","author":"Tricou","year":"2023","journal-title":"PloS NeglTrop Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2254964","article-title":"An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life","volume":"19","author":"Patel","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.01.007","article-title":"A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis A (HAV) virus vaccine in a dengue non-endemic country","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.26633\/rpsp.2021.67","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine in dengue-na\u00efve adolescents in Mexico City","volume":"45","author":"Biswal","year":"2021","journal-title":"Rev Panam Salud Publica"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"B101","unstructured":"Serologic Tests for Dengue Virus\n          \n          2024"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222112004","article-title":"Development and characterization of a multiplex assay to quantify complement-fixing antibodies against dengue virus","volume":"22","author":"Nascimento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"100841","DOI":"10.1016\/j.medj.2025.100841","article-title":"Dengue virus infection reprograms baseline innate immune gene expression","volume":"6","author":"Ong","year":"2025","journal-title":"Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41541-023-00670-6","article-title":"Bridging the immunogenicity of a tetravalent dengue vaccine (Tak-003) from children and adolescents to adults","volume":"8","author":"LeFevre","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3151","article-title":"Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection","volume":"14","author":"Dias","year":"2022","journal-title":"Sci Transl Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115613","article-title":"Anti-dengue virus antibodies that elicit complement-mediated lysis of Zika virion correlate with protection from severe dengue disease","volume":"44","author":"Dias","year":"2025","journal-title":"Cell Rep"},{"key":"B107","article-title":"T-cell immunogenicity to TAK-003 in children and adults following tetravalent dengue vaccination: a comparative analysis","author":"Mandaric","year":"2026"},{"key":"B108","article-title":"Efficacy and safety of a booster dose of the tetravalent dengue vaccine Tak-003 in healthy children in dengue endemic regions (Den-301)","author":"Escudero","year":"2025"},{"key":"B109","article-title":"Long-term safety before and after booster of tetravalent dengue vaccine Tak-003 in healthy adults in dengue nonendemic United States","author":"Escudero","year":"2025"},{"key":"B110","article-title":"Long-term safety before and after booster of tetravalent dengue vaccines Tak-003 in healthy adolescents in dengue nonendemic Mexico","author":"Macias Parra","year":"2025"},{"key":"B111","unstructured":"Qdenga: Assessment Report\n          \n          2022"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126309","article-title":"Early onset of protection of the Tak-003 dengue vaccine: Data from the Den-301 clinical trial","volume":"42","author":"Petri","year":"2024","journal-title":"Vaccine"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2026.106707","article-title":"The DENGVAC study: Preliminary findings on the immunogenicity of the TAK-003 dengue vaccine","volume":"92","author":"D'Abramo","year":"2026","journal-title":"J Infect"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf145","article-title":"Estimated efficacy of Tak-003 against asymptomatic dengue infection in children and adolescents participating in the Den-301 trial in Asia Pacific and Latin America","volume":"231","author":"El Hindi","year":"2025","journal-title":"J Infect Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar4297","article-title":"Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory Cd4 T cells","volume":"4","author":"Saron","year":"2018","journal-title":"Sci Adv"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh3067","article-title":"Insights into dengue immunity from vaccine trials","volume":"15","author":"Ooi","year":"2023","journal-title":"Sci Transl Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: Hypotheses to understand Cyd-Tdv-induced protection","volume":"14","author":"Guy","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-Dv in adults in Brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04255-3","article-title":"Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine","volume":"32","author":"Kall\u00e1s","year":"2026","journal-title":"Nat Med"},{"key":"B123","author":"Tricou","year":"2018","journal-title":"Cell-mediated immunity generated by Takeda's live-attenuated dengue vaccine. 6th Pan American Dengue Research Network Meeting"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1851238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:29Z","timestamp":1784699669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1851238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2026.1851238"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1851238","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1851238"}}